Mabwell (688062.SH) Receives NMPA Approval for 9MW5211 Injection Clinical Trial Application

Stock News07-31

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) has announced that it has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The approval covers the clinical trial application for 9MW5211 injection for the treatment of primary biliary cholangitis (PBC).

Previously, clinical trial applications for 9MW5211 injection for inflammatory bowel disease (IBD) were approved by both the NMPA and the FDA. Additionally, approvals for indications including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), and vitiligo have been obtained from the NMPA. The company is also actively advancing clinical trial applications for other indications.

9MW5211 is a novel, highly specific, depleting antibody developed independently by Mabwell. It targets a key pathological mechanism driven by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells are core drivers in the development of various autoimmune conditions. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a crucial biological marker of their abnormal activation. By selectively recognizing and eliminating these pathogenic cells, 9MW5211 effectively blocks the immune cascade, thus alleviating disease progression and improving clinical symptoms.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139319370?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139319370","market":"hk","top_or_hot":-1,"title":"Mabwell (688062.SH) Receives NMPA Approval for 9MW5211 Injection Clinical Trial Application","media":"Stock News","content":"<p><b>Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH)</b> has announced that it has received a \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The approval covers the clinical trial application for 9MW5211 injection for the treatment of primary biliary cholangitis (PBC).<br><br>Previously, clinical trial applications for 9MW5211 injection for inflammatory bowel disease (IBD) were approved by both the NMPA and the FDA. Additionally, approvals for indications including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), and vitiligo have been obtained from the NMPA. The company is also actively advancing clinical trial applications for other indications.<br><br>9MW5211 is a novel, highly specific, depleting antibody developed independently by <b>Mabwell</b>. It targets a key pathological mechanism driven by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells are core drivers in the development of various autoimmune conditions. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a crucial biological marker of their abnormal activation. By selectively recognizing and eliminating these pathogenic cells, 9MW5211 effectively blocks the immune cascade, thus alleviating disease progression and improving clinical symptoms.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell (688062.SH) Receives NMPA Approval for 9MW5211 Injection Clinical Trial Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell (688062.SH) Receives NMPA Approval for 9MW5211 Injection Clinical Trial Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-31 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH)</b> has announced that it has received a \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The approval covers the clinical trial application for 9MW5211 injection for the treatment of primary biliary cholangitis (PBC).<br><br>Previously, clinical trial applications for 9MW5211 injection for inflammatory bowel disease (IBD) were approved by both the NMPA and the FDA. Additionally, approvals for indications including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), and vitiligo have been obtained from the NMPA. The company is also actively advancing clinical trial applications for other indications.<br><br>9MW5211 is a novel, highly specific, depleting antibody developed independently by <b>Mabwell</b>. It targets a key pathological mechanism driven by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells are core drivers in the development of various autoimmune conditions. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a crucial biological marker of their abnormal activation. By selectively recognizing and eliminating these pathogenic cells, 9MW5211 effectively blocks the immune cascade, thus alleviating disease progression and improving clinical symptoms.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02493","symbol_name":"迈威生物-B","start_time":0,"source_url":"","article_id":"1139319370","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139319370","pubTimestamp":1785492637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) has announced that it has received a \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688062":"迈威生物-U","02493":"迈威生物-B","MDTX":"Corgi MediaTek 2x Daily ETF","BK0239":"医药制造","BMED":"iShares Health Innovation Active ETF","BK1161":"生物科技","PSYK":"PSYK ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF"},"translate_title":"Mabwell(688062.SH)9MW5211注射液临床试验申请获NMPA批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":1,"02493":1,"MDTX":1,"IBBJ":1,"IBBQ":1,"PSYK":1,"BMED":1},"content_text":"Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) has announced that it has received a \"Drug Clinical Trial Approval Notice\" from the National Medical Products Administration (NMPA). The approval covers the clinical trial application for 9MW5211 injection for the treatment of primary biliary cholangitis (PBC).Previously, clinical trial applications for 9MW5211 injection for inflammatory bowel disease (IBD) were approved by both the NMPA and the FDA. Additionally, approvals for indications including multiple sclerosis (MS), type 1 diabetes mellitus (T1DM), and vitiligo have been obtained from the NMPA. The company is also actively advancing clinical trial applications for other indications.9MW5211 is a novel, highly specific, depleting antibody developed independently by Mabwell. It targets a key pathological mechanism driven by abnormal immune cells in autoimmune diseases. The abnormal activation and tissue infiltration of immune cells are core drivers in the development of various autoimmune conditions. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as a crucial biological marker of their abnormal activation. By selectively recognizing and eliminating these pathogenic cells, 9MW5211 effectively blocks the immune cascade, thus alleviating disease progression and improving clinical symptoms.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139319370","isCrawlerRequest":true}